Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?
Siddon AJ, Rinder HM, Hendrickson JE, Tormey CA. Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage? Annals Of Hematology 2015, 94: 1413-1414. PMID: 26027859, DOI: 10.1007/s00277-015-2406-z.Peer-Reviewed Original ResearchNovel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal
Gehrie E, Tormey C. Novel Oral Anticoagulants: Efficacy, Laboratory Measurement, and Approaches to Emergent Reversal. Archives Of Pathology & Laboratory Medicine 2015, 139: 687-92. PMID: 25927153, DOI: 10.5858/arpa.2013-0677-rs.Peer-Reviewed Original ResearchConceptsNovel oral anticoagulantsManagement of NOACOral direct thrombin inhibitorDirect factor Xa inhibitorVitamin K antagonistsDirect thrombin inhibitorFactor Xa inhibitorsCertain clinical circumstancesOral anticoagulationWarfarin effectivenessK antagonistsOral anticoagulantsClinical efficacySafety profileEmergent reversalClinical circumstancesXa inhibitorsUS FoodDrug AdministrationThrombin inhibitorsNew drugsDrugsEfficacyInhibitorsLaboratory assays